These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 23631389

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
    Winn BA, Devkota L, Kuch B, MacDonough MT, Strecker TE, Wang Y, Shi Z, Gerberich JL, Mondal D, Ramirez AJ, Hamel E, Chaplin DJ, Davis P, Mason RP, Trawick ML, Pinney KG.
    J Nat Prod; 2020 Apr 24; 83(4):937-954. PubMed ID: 32196334
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs.
    Pettit GR, Lippert JW.
    Anticancer Drug Des; 2000 Jun 24; 15(3):203-16. PubMed ID: 11049088
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
    Liu T, Zhang D, Song W, Tang Z, Zhu J, Ma Z, Wang X, Chen X, Tong T.
    Acta Biomater; 2017 Apr 15; 53():179-189. PubMed ID: 28167300
    [Abstract] [Full Text] [Related]

  • 13. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
    Gu Y, Ma J, Fu Z, Xu Y, Gao B, Yao J, Xu W, Chu K, Chen J.
    Int J Nanomedicine; 2019 Apr 15; 14():8805-8818. PubMed ID: 31806973
    [Abstract] [Full Text] [Related]

  • 14. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug.
    Pettit GR, Rhodes MR.
    Anticancer Drug Des; 1998 Apr 15; 13(3):183-91. PubMed ID: 9595032
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Visible Light Controlled Release of Anticancer Drug through Double Activation of Prodrug.
    Hossion AM, Bio M, Nkepang G, Awuah SG, You Y.
    ACS Med Chem Lett; 2013 Jan 10; 4(1):124-7. PubMed ID: 24900573
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs.
    Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, Bansal N.
    Anticancer Drug Des; 1995 Jun 10; 10(4):299-309. PubMed ID: 7786396
    [Abstract] [Full Text] [Related]

  • 19. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
    Elsadek B, Graeser R, Esser N, Schäfer-Obodozie C, Abu Ajaj K, Unger C, Warnecke A, Saleem T, El-Melegy N, Madkor H, Kratz F.
    Eur J Cancer; 2010 Dec 10; 46(18):3434-44. PubMed ID: 20933385
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.